Pharma By David Armstrong — ProPublica Watch: In never-before-seen video, Purdue’s Richard Sackler defends OxyContin marketing
First Opinion By Richard A. "Red" Lawhern Stop persecuting doctors for legitimately prescribing opioids for chronic pain
First Opinion By Kate M. Nicholson, Diane E. Hoffman, and Chad D. Kollas Overzealous use of the CDC’s opioid prescribing guideline is harming pain patients
First Opinion By Stefan G. Kertesz and Kate M. Nicholson No more ‘shortcuts’ in prescribing opioids for chronic pain. Millions of Americans need nuanced care
Special Report By Julie Appleby and Elizabeth Lucas — Kaiser Health News While addiction crisis raged, many surgeons overprescribed opioids, analysis shows
Special Report By Casey Ross, Max Blau, and Kate Sheridan Medicine with a side of mysticism: Top hospitals promote unproven therapies
First Opinion By Nkeiruka Orajiaka Some kids in pain need opioids. For doctors, that means walking a tightrope
Health By Ruth Hailu ‘Sickle cell needs more funding’: An 18-year-old patient advocate calls on Washington to improve children’s health care
First Opinion By Ben Goodwin, Judy Butler, and Adriane Fugh-Berman Industry-funded attacks on the CDC’s opioid prescribing guideline are eroding public health
First Opinion By William Fleischman and Joseph S. Ross How Insys undermined an FDA effort to protect the public from dangerous opioids
In the Lab By Jacquelyn Corley The case of a woman who feels almost no pain leads scientists to a new gene mutation
First Opinion By Dave Chase The opioid crisis is partly fueled by insurers’ and employers’ approach to back pain
Health By Lev Facher Study shows Purdue’s switch to ‘abuse-deterrent’ OxyContin helped drive a spike in hepatitis C infections
Health By Damian Garde So good it hurts: Why drug makers looking to replace opioids want to keep some pain in the picture
Health By Casey Ross Once a last resort, this pain therapy is getting a new life amid the opioid crisis
Health By Lev Facher Kaleo, maker of $4,100 overdose antidote, authorizes a generic version for just $178
The Pharmalot View By Ed Silverman The military pushed it for the battlefield. The FDA went along. Is the newest opioid any better?
In the Lab By Adam Feuerstein One to watch at ASH18: She’s 17 and she studies chronic pain in sickle cell disease
Health By Associated Press Medical devices for pain, other conditions have caused more than 80,000 deaths since 2008
First Opinion By Maia Dolphin-Krute Viewing the opioid crisis as an ecological disaster could help with ‘cleanup’
Health By Lev Facher Tapered to zero: In radical move, Oregon’s Medicaid program weighs cutting off chronic pain patients from opioids